Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma

November 13th 2023

Bayer has announced the intention to voluntarily withdraw the new drug application for copanlisib in adult patients with relapsed follicular lymphoma who have previously received at least 2 prior systemic treatments.

Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm

November 9th 2023

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.

FDA Places Partial Clinical Hold on Phase 1 Trial of NX-2127 in R/R B-Cell Malignancies

November 2nd 2023

The FDA has placed a partial clinical hold on the phase 1 NX-2127-001 trial investigating the novel BTK degrader NX-2127 in patients with relapsed/refractory B-cell malignancies.

FDA Grants Fast Track Designation to SLS009 for Relapsed/Refractory PTCL

October 31st 2023

The FDA has granted a fast track designation to SLS009 for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

October 30th 2023

Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.

Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy

October 24th 2023

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to epcoritamab-bysp monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapy.

Frontline VR-CAP Is Effective and Well Tolerated in MZL

October 23rd 2023

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population

October 23rd 2023

The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.

Novel Bispecific Antibody EX103 Demonstrates Safety, Elicits Preliminary Antitumor Activity in R/R B-Cell NHL

October 23rd 2023

The novel CD20xCD3 bispecific antibody EX103 displayed a favorable safety profile and produced preliminary antitumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma

October 13th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib in combination with obinutuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic treatment.

FDA Grants Priority Review to Odronextamab in Relapsed/Refractory Follicular Lymphoma or DLBCL

September 29th 2023

The FDA has granted priority review to the biologics license application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma who have progressed after at least 2 prior systemic therapies.

Deeper Understanding of immune System Could Advance Treatment Options in Lymphoma

September 26th 2023

Stephen M. Ansell, MD, PhD, discusses the successes and challenges of utilizing immune therapy across the landscape of hematologic malignancies, the importance of increasing the understanding of how the immune system functions in patients with lymphoma, and ongoing research of immune therapy for this patient population.

Epcoritamab Wins European and Japanese Approval for Select Types of R/R LBCL

September 25th 2023

Epcoritamab-bysp has been approved by the European Commission and Japan's Ministry of Health, Labour, and Welfare for the treatment of select patients with relapsed/refractory large B-cell lymphoma.

Novel Combinations Seek to Build Off Lenalidomide/Rituximab Backbone in Indolent Lymphoma

September 25th 2023

Paolo Strati, MD, discusses novel combinations for the treatment of indolent B-cell lymphoma, emphasizes the primary goal of improving the efficacy of immunotherapy and providing patients with chemotherapy-free treatment options, and highlights ongoing trials are investigating various approaches to enhance the activity of lenalidomide/rituximab

SLS009 Demonstrates Activity, Safety in Relapsed/Refractory Lymphoma

September 21st 2023

Treatment with SLS009 generated clinical activity and was safe in patients with relapsed/refractory lymphomas.

Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FL

September 19th 2023

Peter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.

FDA Grants Fast Track Designation to KT-333 in R/R CTCL and PTCL

September 18th 2023

The FDA has granted fast track designation to KT-333 for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma and relapsed/refractory peripheral T-cell lymphoma.

Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma

September 15th 2023

Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.

Dr. Ansell on the Development of Potential Immune-Harnessing Therapeutics in Lymphoma

September 14th 2023

Stephen M. Ansell, MD, PhD, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes.

Golidocitinib NDA Under NMPA Review for Relapsed/Refractory PTCL

September 14th 2023

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of golidocitinib for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.